title: Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome.
abstract: Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) was examined in vitro in 23 patients with aplastic anemia and 14 with myelodysplastic syndrome (MDS) to investigate the clinical use of rh-Ep for these diseases. Bone marrow mononuclear cells were cultured by methylcellulose methods for CFU-E and BFU-E assays. In normals, the CFU-E numbers reached a plateau of increase at Ep doses of almost 2-5 units, and no further increase was observed with the addition of larger Ep doses. In aplastic anemia, the responses of CFU-E to Ep were relatively good in nonsevere type and generally poor in severe type. However, the CFU-E numbers increased with increasing doses of Ep in some of the patients with aplastic anemia. Among the patients with MDS, the responses of CFU-E to Ep were relatively good in primary acquired refractory anemia (PARA) and primary acquired sideroblastic anemia. On the other hand, the responses of CFU-E to Ep were poor in refractory anemia with an excess of blasts (RAEB) and RAEB in transformation among the MDS patients. BFU-E responses to Ep were poor in severe aplastic anemia, RAEB, and RAEB-T. However, there are Ep responsive patients in some of aplastic anemia and PARA. High titers of rh-Ep were suggested to be effective clinically in some patients with aplastic anemia and those with PARA.
authors.affiliation: Second Department of Internal Medicine, Kyorin University, School of Medicine, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Aoki
authors.forename: K
authors.initials: K
authors.lastname: Higashi
authors.forename: M
authors.initials: M
authors.lastname: Homori
authors.forename: H
authors.initials: H
authors.lastname: Chikazawa
authors.forename: K
authors.initials: K
authors.lastname: Ishikawa
mesh_terms: D000741:Anemia, Aplastic / Q000473:pathology*; D000753:Anemia, Refractory / Q000473:pathology; D000754:Anemia, Refractory, with Excess of Blasts / Q000473:pathology; D000756:Anemia, Sideroblastic / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D015672:Erythroid Precursor Cells / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000473:pathology*; D011994:Recombinant Proteins; D012016:Reference Values
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin